在斋月期间SGLT2抑制剂对2型糖尿病患者功能的影响:系统性审查
Muhammad Aamir Waheed1, Salah Ali Saleh Diffala Suwileh2, Khalid Rashid3
1College of Medicine, Hamad General Hospital, Qatar University, Doha, Qatar *Email: mawaheedhmc@yahoo.com.
Qatar medical journal
|June 27, 2024
概括
在斋月禁食期间,2型糖尿病患者使用的-葡萄糖共运输体2 (SGLT2) 抑制剂没有显著改变功能. 这一系统性审查表明,SGLT2抑制剂在斋月期间对脏健康是安全的.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂具有透性利尿性质.
- 在斋月禁食期间使用SGLT2抑制剂可能会增加体积枯竭的风险,并影响2型糖尿病患者的功能.
研究的目的:
- 系统地审查SGLT2抑制剂对遵守斋月禁食的2型糖尿病患者功能的影响.
- 评估估计的膜过率 (eGFR) 和肌水平的变化.
主要方法:
- 来自PubMed,EMBASE和Cochrane中央注册的受控研究 (2013-2023) 的系统审查.
- 包括的研究集中在成人2型糖尿病患者,在禁食期间使用SGLT2抑制剂,报告功能结果.
- 在PROSPERO的注册号是CRD42020204582.
主要成果:
- 分析了两项前性观察性研究,共359名参与者 (197名SGLT2抑制剂).
- 在斋月期间使用SGLT2抑制剂的患者中没有观察到EGFR的显著变化.
- 具体的研究显示了非显著的平均eGFR变化:Hassanein等人. (-1.2 ± 19.4 对比3.1 ± 14.8,p=0.06) 和肖等人. (-6.0 ± 1.5 与 -4.2 ± 1.6 相比,p=0.39)).这是一个很大的变化.
结论:
- 尽管研究有限,但在斋月禁食期间在2型糖尿病患者中使用SGLT2抑制剂不会显著影响功能.
- 研究结果表明,糖尿病患者在斋月期间可以安全使用SGLT2抑制剂,没有明显的脏不良影响.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199


